Hubbry Logo
Thymosin beta-4Thymosin beta-4Main
Open search
Thymosin beta-4
Community hub
Thymosin beta-4
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Thymosin beta-4
Thymosin beta-4
Thymosin beta-4
View on Wikipedia
from Wikipedia

TMSB4X
Available structures
PDBHuman UniProt search: PDBe RCSB
Identifiers
AliasesTMSB4X, FX, PTMB4, TB4X, TMSB4, thymosin beta 4, X-linked, thymosin beta 4 X-linked
External IDsOMIM: 300159; GeneCards: TMSB4X; OMA:TMSB4X - orthologs
Orthologs
SpeciesHumanMouse
Entrez

7114

n/a

Ensembl

ENSG00000205542

n/a

UniProt

P62328

n/a

RefSeq (mRNA)

NM_021109

n/a

RefSeq (protein)

NP_066932

n/a

Location (UCSC)Chr X: 12.98 – 12.98 Mbn/a
PubMed search[2]n/a
Wikidata
View/Edit Human

Thymosin beta-4 is a protein that in humans is encoded by the TMSB4X gene.[3][4][5] Recommended INN (International Nonproprietary Name) for thymosin beta-4 is 'timbetasin', as published by the World Health Organization (WHO).[6]

The protein consists (in humans) of 43 amino acids (sequence: SDKPDMAEI EKFDKSKLKK TETQEKNPLP SKETIEQEKQ AGES) and has a molecular weight of 4921 g/mol.[7]

Thymosin-β4 is a major cellular constituent in many tissues. Its intracellular concentration may reach as high as 0.5 mM.[8] Following Thymosin α1, β4 was the second of the biologically active peptides from Thymosin Fraction 5 to be completely sequenced and synthesized.[9]

Function

[edit]

This gene encodes an actin sequestering protein which plays a role in regulation of actin polymerization. The protein is also involved in cell proliferation, migration, and differentiation. This gene escapes X inactivation and has a homolog on chromosome Y (TMSB4Y).[5]

Biological activities of thymosin β4

[edit]

Any concepts of the biological role of thymosin β4 must inevitably be coloured by the demonstration that total ablation of the thymosin β4 gene in the mouse allows apparently normal embryonic development of mice which are fertile as adults.[10]

Actin binding

[edit]

Thymosin β4 was initially perceived as a thymic hormone. However this changed when it was discovered that it forms a 1:1 complex with G (globular) actin, and is present at high concentration in a wide range of mammalian cell types.[11] When appropriate, G-actin monomers polymerize to form F (filamentous) actin, which, together with other proteins that bind to actin, comprise cellular microfilaments. Formation by G-actin of the complex with β-thymosin (= "sequestration") opposes this.[citation needed]

Due to its profusion in the cytosol and its ability to bind G-actin but not F-actin, thymosin β4 is regarded as the principal actin-sequestering protein in many cell types. Thymosin β4 functions like a buffer for monomeric actin as represented in the following reaction:[12]

F-actin ↔ G-actin + Thymosin β4 ↔ G-actin/Thymosin β4

Release of G-actin monomers from thymosin β4 occurs as part of the mechanism that drives actin polymerization in the normal function of the cytoskeleton in cell morphology and cell motility.

The sequence LKKTET, which starts at residue 17 of the 43-aminoacid sequence of thymosin beta-4, and is strongly conserved between all β-thymosins, together with a similar sequence in WH2 domains, is frequently referred to as "the actin-binding motif" of these proteins, although modelling based on X-ray crystallography has shown that essentially the entire length of the β-thymosin sequence interacts with actin in the actin-thymosin complex.[13]

"Moonlighting"

[edit]

In addition to its intracellular role as the major actin-sequestering molecule in cells of many multicellular animals, thymosin β4 shows a remarkably diverse range of effects when present in the fluid surrounding animal tissue cells. Taken together, these effects suggest that thymosin has a general role in tissue regeneration. This has suggested a variety of possible therapeutic applications, and several have now been extended to animal models and human clinical trials.[citation needed]

It is considered unlikely that thymosin β4 exerts all these effects via intracellular sequestration of G-actin. This would require its uptake by cells, and moreover, in most cases the cells affected already have substantial intracellular concentrations.[citation needed]

The diverse activities related to tissue repair may depend on interactions with receptors quite distinct from actin and possessing extracellular ligand-binding domains. Such multi-tasking by, or "partner promiscuity" of, proteins has been referred to as protein moonlighting.[14] Proteins such as thymosins which lack stable folded structure in aqueous solution, are known as intrinsically unstructured proteins (IUPs). Because IUPs acquire specific folded structures only on binding to their partner proteins, they offer special possibilities for interaction with multiple partners.[15] A candidate extracellular receptor of high affinity for thymosin β4 is the β subunit of cell surface-located ATP synthase, which would allow extracellular thymosin to signal via a purinergic receptor.[16]

Some of the multiple activities of thymosin β4 unrelated to actin may be mediated by a tetrapeptide enzymically cleaved from its N-terminus, N-acetyl-ser-asp-lys-pro, brand names Seraspenide or Goralatide, best known as an inhibitor of the proliferation of haematopoietic (blood-cell precursor) stem cells of bone marrow.

Tissue regeneration
[edit]

Work with cell cultures and experiments with animals have shown that administration of thymosin β4 can promote migration of cells, formation of blood vessels, maturation of stem cells, survival of various cell types and lowering of the production of pro-inflammatory cytokines. These multiple properties have provided the impetus for a worldwide series of on-going clinical trials of potential effectiveness of thymosin β4 in promoting repair of wounds in skin, cornea and heart.[17]

Such tissue-regenerating properties of thymosin β4 may ultimately contribute to repair of human heart muscle damaged by heart disease and heart attack. In mice, administration of thymosin β4 has been shown to stimulate formation of new heart muscle cells from otherwise inactive precursor cells present in the outer lining of adult hearts,[18] to induce migration of these cells into heart muscle[19] and recruit new blood vessels within the muscle.[20]

Anti-inflammatory role for sulfoxide
[edit]

In 1999 researchers in Glasgow University found that an oxidised derivative of thymosin β4 (the sulfoxide, in which an oxygen atom is added to the methionine near the N-terminus) exerted several potentially anti-inflammatory effects on neutrophil leucocytes. It promoted their dispersion from a focus, inhibited their response to a small peptide (F-Met-Leu-Phe) which attracts them to sites of bacterial infection and lowered their adhesion to endothelial cells. (Adhesion to endothelial cells of blood vessel walls is pre-requisite for these cells to leave the bloodstream and invade infected tissue). A possible anti-inflammatory role for the β4 sulfoxide was supported by the group's finding that it counteracted artificially-induced inflammation in mice.[citation needed]

The group had first identified the thymosin sulfoxide as an active factor in culture fluid of cells responding to treatment with a steroid hormone, suggesting that its formation might form part of the mechanism by which steroids exert anti-inflammatory effects. Extracellular thymosin β4 would be readily oxidised to the sulfoxide in vivo at sites of inflammation, by the respiratory burst.[21]

Terminal deoxynucleotidyl transferase
[edit]

Thymosin β4 induces the activity of the enzyme terminal deoxynucleotidyl transferase in populations of thymocytes (thymus-derived lymphocytes). This suggests that the peptide may contribute to the maturation of these cells.[9]

Clinical significance

[edit]

Tβ4 has been studied in a number of clinical trials.[22]

In phase 2 trials with patients having pressure ulcers, venous pressure ulcers, and epidermolysis bullosa, Tβ4 accelerated the rate of repair. It was also found to be safe and well tolerated.[23]

In human clinical trials, Tβ4 improves the conditions of dry eye and neurotrophic keratopathy with effects lasting long after the end of treatment.[24]

See also: Thymosin_beta-4 § Tissue_regeneration

Doping in sports

[edit]
See also: Essendon Football Club supplements saga and Drugs in sport in Australia

Thymosin beta-4 is considered a performance enhancing substance and is banned in sports by the World Anti-Doping Agency due to its effect of aiding soft tissue recovery and enabling higher training loads.[25] It was central to two controversies in Australia in the 2010s which saw a large proportion of the playing lists from two professional football clubs – the Cronulla-Sutherland Sharks of the National Rugby League and the Essendon Football Club of the Australian Football League – found guilty of doping and suspended from playing; in both cases, the players were administered thymosin beta-4 in a program organised by sports scientist Stephen Dank.[26][27][28]

Interactions

[edit]

TMSB4X has been shown to interact with ACTA1[29][30] and ACTG1.[31][32]

See also

[edit]

References

[edit]

Further reading

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Thymosin beta-4

View on Grokipedia
from Grokipedia
Thymosin beta-4 (Tβ4) is a small, ubiquitous 43-amino-acid encoded by the X-linked TMSB4X , featuring an acetylated serine at its and functioning primarily as an actin-sequestering protein that binds G-actin monomers to inhibit and regulate cytoskeletal dynamics. Expressed across diverse tissues, Tβ4 influences , migration, and differentiation through its modulation of actin sequestration and additional signaling pathways. Beyond cytoskeletal regulation, Tβ4 promotes , accelerates , and exhibits anti-inflammatory effects, contributing to tissue repair and maintenance in various physiological contexts. These properties have spurred research into its therapeutic potential for conditions involving tissue damage, such as and corneal injuries, where it enhances cell survival and functional recovery. However, Tβ4 also correlates with pathological processes, including increased tumor cell metastatic potential and in cancers, highlighting a dual role that necessitates cautious application in . Studies in models indicate Tβ4 is dispensable for embryonic cardiac development and adult myocardial function, underscoring that while beneficial in repair, it is not essential for baseline organ formation.

Discovery and Structure

Historical Discovery and Isolation

Thymosins, a family of peptides extracted from the gland, were first studied in the early by Abraham White and colleagues at the Albert Einstein College of Medicine, who demonstrated that thymic extracts could restore immune function in thymectomized animals. This work laid the foundation for identifying specific thymic factors, with Allan L. Goldstein advancing the research after joining White's lab and later establishing independent efforts at the . In 1972, Goldstein's team prepared thymosin fraction 5 (TF5), a partially purified extract from calf glands processed through acid-acetone extraction, , and gel filtration, which exhibited potent thymic hormone-like activity in restoring T-cell differentiation. TF5 contained multiple low-molecular-weight peptides, prompting systematic purification to isolate individual components responsible for biological effects. Thymosin beta-4 (Tβ4), the most abundant beta-thymosin isoform, was first isolated from calf thymus as part of this purification effort in the late 1970s. Using techniques including ion-exchange chromatography on carboxymethylcellulose columns in acetate buffer with mercaptoethanol, followed by reverse-phase , Terence L. K. Low, Shi-Kang Hu, and Allan L. Goldstein purified Tβ4 to homogeneity and determined its complete , published in 1981. The , comprising 43 with an N-terminal acetylserine, was initially classified as a potential thymic due to its presence in TF5 and observed effects on maturation, though subsequent studies revealed its ubiquitous expression across tissues rather than thymic specificity.

Molecular Composition and Domains

Thymosin beta-4 is a small, 43-amino acid polypeptide with a calculated molecular weight of 4,982 Da and an isoelectric point of 5.1. Its primary sequence in humans is acetyl-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser, featuring N-terminal acetylation and no cysteine residues, which prevents intramolecular disulfide bridges. The sequence is highly conserved across vertebrates, reflecting its fundamental role in actin regulation. The protein exhibits an intrinsically disordered conformation in isolation, adopting an extended α-helical structure upon binding to globular (G-actin). Lacking modular subdomains, thymosin beta-4 functions as a single β-thymosin/WH2 domain that spans approximately residues 1-43, enabling high-affinity sequestration of G-actin monomers with a of 0.4-0.7 μM.00403-9) This domain contacts actin subdomains 1 and 3, sterically occluding both the barbed and pointed ends to inhibit and while modulating exchange. Key residues within the domain, such as those in the LKKTET motif (residues 17-22), contribute to actin affinity and have been implicated in additional signaling activities independent of sequestration.

Biochemical Mechanisms

Actin Binding and Polymerization Regulation

Thymosin beta-4 (Tβ4), a 43-amino-acid with a molecular weight of approximately 5 , functions primarily as a sequestering agent for globular (G-actin) monomers in eukaryotic cells, maintaining a pool of unpolymerized available for rapid cytoskeletal remodeling. It forms a 1:1 stoichiometric complex with G-actin, binding with high specificity to the ATP-bound form and exhibiting a (Kd) in the range of 0.7–1 μM, which effectively inhibits spontaneous and elongation into filamentous (F-actin). This sequestration raises the critical concentration of free G-actin required for , thereby regulating the dynamics of assembly and disassembly essential for cellular motility, , and formation. Structurally, Tβ4 adopts an extended, largely unstructured conformation in solution but folds into two α-helices upon binding G-actin: an N-terminal amphipathic helix that contacts the barbed-end face of actin and a C-terminal helix that engages the pointed-end subdomain, effectively capping both polymerization-competent ends of the monomer. This dual-end occlusion sterically hinders actin-actin interactions necessary for filament growth, while also stabilizing the ATP-bound state of G-actin by inhibiting nucleotide exchange, which further slows depolymerization from filament ends under physiological conditions. Crystal structures of the Tβ4–G-actin complex, resolved at 1.7 Å resolution, confirm these interactions, revealing key residues such as Lys-38 of Tβ4 cross-linking to Gln-41 of actin, underscoring the precision of this inhibitory mechanism. In cellular contexts, Tβ4's sequestration modulates by competing with other actin-binding proteins like , which can facilitate actin addition to filament barbed ends via exchange from the Tβ4-bound pool; however, at typical intracellular concentrations (up to 0.5 mM in some tissues), Tβ4 predominates in maintaining monomeric actin reservoirs. While primarily inhibitory, elevated Tβ4 levels can weakly promote F-actin binding and bundling , suggesting context-dependent roles beyond pure sequestration, though this occurs at non-physiological concentrations exceeding 10 μM. TB-500, a synthetic fragment of thymosin beta-4 typically consisting of an N-terminal 17-amino-acid sequence, mimics these actin regulation properties by sequestering G-actin monomers and modulating polymerization dynamics, potentially contributing to enhanced tissue resilience and recovery processes in preclinical models. These properties position Tβ4 as a key rheostat for , with disruptions in its binding linked to altered rates in pathological states such as , where Tβ4 supplementation has been shown to mitigate excessive F-actin formation and improve outcomes in experimental models.

Moonlighting Functions Beyond Actin Dynamics

Thymosin β4 (Tβ4) demonstrates moonlighting activities distinct from its primary role in sequestering G- monomers, encompassing , cardioprotective, and anti-fibrotic effects mediated through pathways such as modulation of signaling and responses. These functions arise from Tβ4's interaction with intracellular signaling cascades and extracellular environments, often independent of cytoskeletal remodeling. For instance, Tβ4 , an oxidized derivative generated during , exhibits enhanced potency by promoting resolution of inflammatory responses without reliance on dynamics. In anti-inflammatory contexts, Tβ4 suppresses pro-inflammatory mediator expression by inhibiting TNF-α-induced activation and reducing IL-8 release in epithelial cells, thereby attenuating endotoxin-induced . This occurs through downregulation of inflammatory cytokines like IL-6 and TNF-α, as observed in models of alcoholic where Tβ4 mitigated hepatic independently of actin-related pathways. Similarly, in LPS- and ATP-stimulated hepatic stellate cells, Tβ4 curbs inflammatory signaling via and MAPK pathways, highlighting its role in resolving sterile . These effects extend to models, where Tβ4 limits joint without direct cytoskeletal involvement. Cardioprotective roles of Tβ4 involve preservation of myocardial function post-ischemia, including reduced infarct size and prevention of cardiac rupture after myocardial infarction, achieved via promotion of cell survival and inhibition of apoptosis rather than actin polymerization. In angiotensin II-induced hypertension models, Tβ4 deficiency exacerbated renal and cardiac injury, underscoring its endogenous protective function against oxidative damage through antioxidant enzyme upregulation, such as thioredoxin-interacting protein modulation. Tβ4 also targets anti-apoptotic pathways in oxidative stress conditions, enhancing cardiomyocyte viability independently of actin sequestration. Anti-fibrotic properties further illustrate Tβ4's multifunctional nature, as it attenuates in wounded tissues by limiting inflammatory cell infiltration and deposition, as evidenced in dermal and hepatic injury models. In these settings, Tβ4 reduces fibrotic and accumulation without altering filament assembly. Collectively, these moonlighting functions position Tβ4 as a pleiotropic regulator, with therapeutic implications in inflammatory and degenerative diseases, though mechanisms require further elucidation beyond actin-centric models.

Physiological and Regenerative Roles

Wound Healing and Tissue Repair

Thymosin β4 (Tβ4) facilitates through multiple mechanisms, including sequestration of G-actin to promote F-actin , which enhances and endothelial cell migration essential for re-epithelialization and tissue remodeling. It upregulates (VEGF) and basic fibroblast growth factor (bFGF) via pathways such as PI3K/Akt/eNOS and Notch signaling, thereby stimulating and collagen deposition during the proliferative phase. Additionally, Tβ4 exhibits anti-inflammatory effects by suppressing activation and reducing pro-inflammatory cytokines like TNF-α, while inhibiting through decreased caspase-3/9 expression; it also limits by reducing differentiation, leading to decreased formation. TB-500, a synthetic fragment of Tβ4 corresponding to its active N-terminal region (often the acetylated 17-amino acid sequence Ac-LKKTETQ), mimics these mechanisms to promote tissue repair and recovery. Preclinical studies indicate that TB-500 enhances actin regulation, supporting cell migration and tissue resilience, which may contribute to improved wound healing and endurance recovery in animal models. However, its use remains investigational, primarily in research and veterinary contexts, with limited human data. In preclinical models, topical or systemic Tβ4 administration (e.g., 5 μg in 50 μL for 8 mm full-thickness excisional wounds in rats) accelerates dermal closure in normal, diabetic, aged, and burn-injured , with increased , reduced necrotic areas, and enhanced VEGF expression observed as early as 2015 studies. For instance, in rat models of skin flaps, 5 mg/kg twice daily dosing reduced and promoted survival via upregulated VEGF and β-catenin in 2017 experiments. Similar efficacy extends to corneal wounds in rabbits, where Tβ4 modulates matrix metalloproteinase-2/tissue inhibitor of metalloproteinase-2 balance to hasten re-epithelialization, independent of TGF-β signaling. Clinical evidence from phase II trials supports Tβ4's potential, with 0.03% gel formulations shortening healing time by approximately one month for pressure ulcers in 143 patients and achieving complete closure in 25% of 73 ulcer cases within three months. In wounds, phase II data showed accelerated repair rates comparable to other trial cohorts, with no significant adverse effects across doses up to 1000 μg in phase I safety assessments of 15 volunteers. Tβ4 was well-tolerated, though broader adoption awaits larger phase III validation, as current data indicate investigational status for chronic dermal wounds. These findings underscore Tβ4's role in tissue repair beyond acute wounds, including and corneal regeneration, but emphasize the need for further randomized controlled trials to confirm in diverse human pathologies.

Angiogenesis and Cell Migration

Thymosin beta-4 (Tβ4) promotes through mechanisms involving endothelial , proliferation, and differentiation, as well as upregulation of pro-angiogenic factors. In vitro studies demonstrate that Tβ4 enhances the viability of endothelial progenitor cells (EPCs) and stimulates their proliferation and migration, contributing to the formation of tubular structures indicative of neovascularization. Extracellular Tβ4 further supports vascular stability by inducing differentiation of mesodermal progenitor cells into mature mural cells, including vascular smooth muscle cells, via activation of signaling pathways such as Akt and MAPK. Tβ4 functions as a potent chemoattractant for endothelial cells, significantly enhancing their directional migration. For instance, treatment with Tβ4 increases the migration of human umbilical vein endothelial cells (HUVECs) in Boyden chamber assays by four- to sixfold compared to controls, without inducing proliferation in some experimental conditions. This migratory effect extends to EPCs, where Tβ4 improves endothelial function and reparative capacity, as observed in models of and vascular injury. TB-500, as a synthetic fragment of Tβ4, similarly supports angiogenesis and cell migration by regulating actin dynamics, which may aid in tissue recovery and resilience during regenerative processes. Preclinical evidence suggests it promotes endothelial cell migration and vessel formation, potentially enhancing flexibility and endurance in injury models, though human applications are not approved. Mechanistically, Tβ4 induces expression of (VEGF), amplifying angiogenic signaling through pathways like VEGFR2 activation, which promotes endothelial and reduces in vitro. In vivo, systemic or local administration of Tβ4 accelerates in ischemic models, such as hindlimb ischemia in mice, by elevating VEGF levels and enhancing density. These effects underscore Tβ4's role in coordinating with vessel maturation during regenerative processes like . Furthermore, Tβ4 activates hair follicle stem cells and promotes angiogenesis around hair follicles by stimulating VEGF expression, leading to accelerated hair growth in rat and mouse models.

Anti-inflammatory and Cardioprotective Effects

Thymosin beta-4 (Tβ4) modulates inflammatory responses by downregulating pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, while upregulating mediators like IL-10 in various tissue injury models. In corneal , Tβ4 suppresses activation, a key driving inflammatory , thereby reducing leukocyte infiltration and . These effects extend to , as evidenced in models where Tβ4 decreases (ROS) production, lowers inflammatory mediator levels, and enhances anti-oxidative enzyme activity, contributing to immune . Additionally, Tβ4 promotes resolution of by activating specialized pro-resolving mediator (SPM) pathways, which facilitate clearance of inflammatory cells without compromising host defense. In non-alcoholic fatty liver disease (NAFLD), Tβ4 regulates polarization toward an M2 , reducing hepatic and in mouse models. Its oxidized form, β4-sulfoxide, generated in the presence of glucocorticoids, further attenuates inflammatory cell infiltration and promotes resolution in dermal and cardiac contexts. These mechanisms underscore Tβ4's role in balancing immune responses, though elevated levels in suggest context-dependent effects that may exacerbate chronic in autoimmune conditions. Regarding cardioprotective effects, Tβ4 administration post-myocardial infarction (MI) in preclinical rodent models reduces infarct size by up to 30-50%, preserves left ventricular ejection fraction, and limits adverse remodeling through enhanced cardiomyocyte survival and endothelial migration. Similarly, the synthetic fragment TB-500, a key active region of Tβ4, has shown comparable cardioprotective effects in animal models of heart injury, influencing actin polymerization to promote cell migration and tissue remodeling, while supporting wound healing and anti-inflammatory responses that contribute to improved cardiac repair. It mitigates ischemia-reperfusion injury by inhibiting and , with studies showing decreased deposition and improved when administered systemically within hours of occlusion. Dimeric variants of Tβ4 exhibit enhanced potency, outperforming monomeric forms in echocardiography-assessed ventricular function recovery in MI mice. These benefits partly stem from Tβ4's anti-inflammatory actions in the myocardium, where it curbs post-infarct influx and storms, alongside sequestration that stabilizes cytoskeletal integrity during hypoxic stress. Circulating Tβ4 levels also correlate with first-onset MI risk, positioning it as a potential for early detection.

Clinical Applications and Evidence

Approved and Investigational Uses

Thymosin beta-4 has no approved indications for human therapeutic use by major regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the (EMA). It received designation from the FDA on December 31, 2013, for neurotrophic keratopathy, a rare corneal condition, but has not progressed to approval for this or any other indication. The peptide remains classified as investigational, with availability limited to settings, compounding pharmacies, or unregulated sources, raising concerns over purity and due to lack of standardized manufacturing. Investigational applications of thymosin beta-4 primarily target its roles in tissue repair, , and processes. In , phase 3 clinical trials have evaluated ophthalmic formulations for dry eye disease and neurotrophic keratopathy, conditions involving corneal and reduced tear production, with preliminary data suggesting potential benefits in epithelial healing. For dermatological wounds, phase 2 trials demonstrated accelerated healing in pressure ulcers, stasis ulcers, and lesions when applied topically, attributed to enhanced cell migration and reduced inflammation, though larger confirmatory studies are needed. ulcers have also been studied in phase 2 trials, showing improved closure rates compared to standard care. Preliminary interest has also emerged in its potential for promoting hair growth, with mostly anecdotal reports from peptide therapy clinics suggesting activation of hair follicle stem cells and promotion of angiogenesis around follicles, though robust human clinical trials are lacking. Cardiovascular applications are under exploration, with phase 2 trials assessing intravenous thymosin beta-4 for acute to promote cardiac repair and reduce ischemia-reperfusion injury through and cardiomyocyte protection. Early-phase studies have examined its and in healthy volunteers via intravenous administration, reporting tolerability but noting potential immune responses. Additional preclinical and early human data support investigation in for actin regulation to mitigate , though human efficacy remains unproven. TB-500, a synthetic analogue of thymosin beta-4 consisting of a 17-amino acid fragment, is also investigational and has been explored for enhancing recovery and performance, particularly in musculoskeletal injuries and tissue repair. It is associated with potential improvements in actin regulation, flexibility, endurance recovery, and sustained tissue resilience, primarily based on preclinical studies. However, TB-500 lacks regulatory approval for human use and is prohibited by organizations like the World Anti-Doping Agency for performance enhancement in sports. Overall, while promising in animal models for myocardial ischemia and dermal repair, clinical translation is hindered by inconsistent trial outcomes and regulatory hurdles.

Clinical Trials and Efficacy Data

Thymosin beta-4 (Tβ4) has undergone clinical evaluation primarily in phase I and II trials for ocular conditions, with limited advancement to phase III and sparse efficacy data for non-ocular applications such as and cardiac repair. Most studies, sponsored by RegeneRx Biopharmaceuticals, report safety and preliminary efficacy signals, though no indications have received regulatory approval as of 2025, indicating that results have not yet met thresholds for broad therapeutic validation. In dry eye disease, a phase II randomized, double-masked, vehicle-controlled trial (NCT01387347) enrolled 72 patients with moderate to severe symptoms, administering 0.1% Tβ4 ophthalmic solution four times daily for 28 days. The treatment significantly reduced ocular discomfort scores by 35.1% relative to vehicle (p=0.028) and improved corneal fluorescein staining, a measure of epithelial damage, alongside enhancements in tear breakup time and conjunctival redness. No serious adverse events were linked to Tβ4, supporting its tolerability. Subsequent phase IIb and phase III trials (e.g., NCT02597803) corroborated these outcomes, demonstrating statistically significant improvements in signs like ocular surface staining and symptoms such as discomfort, with effect sizes consistent across studies involving over 200 participants total. However, these trials were relatively small and short-term, limiting generalizability, and long-term efficacy remains unestablished. For neurotrophic keratopathy, a phase II trial of 0.1% Tβ4 showed accelerated corneal epithelial healing, with defect closure rates exceeding those in historical controls, alongside reduced ocular and in patients unresponsive to standard therapies. Efficacy was attributed to Tβ4's role in promoting and anti-apoptotic effects, with no significant safety concerns observed. Phase III trials for this indication were initiated but have not yielded published confirmatory data by 2025. Non-ocular trials have yielded weaker efficacy evidence. A phase II study (NCT00832091) in venous stasis ulcers tested topical Tβ4 doses up to 0.03% twice daily for 12 weeks but found no significant acceleration in wound closure rates compared to placebo, despite good tolerability. Similarly, a phase II trial (NCT00311766) for dystrophic epidermolysis bullosa wounds reported modest improvements in healing but failed to achieve primary endpoints for complete re-epithelialization. In cardiovascular applications, a phase I/II trial (NCT01311518) of injectable Tβ4 in 30 patients with acute myocardial infarction or pressure overload confirmed safety at doses up to 300 µg/kg intravenously but showed no robust improvements in ejection fraction or remodeling markers. Phase I safety studies in healthy volunteers (e.g., NCT04555850) further established pharmacokinetic profiles but provided no efficacy insights. Regarding TB-500, human clinical trials are limited, with efficacy primarily supported by preclinical animal models demonstrating accelerated healing, reduced recovery time in injuries, and potential benefits for performance enhancement through enhanced actin regulation and tissue resilience. Anecdotal and retrospective reports suggest improvements in musculoskeletal recovery, but these lack rigorous controls and statistical validation, underscoring the need for large-scale human studies. Overall, while ocular trials suggest targeted benefits, broader efficacy claims require larger, independent phase III validations to address potential sponsor bias in early data.

Safety Profile and Side Effects

Thymosin beta-4 (TB4) has exhibited a favorable safety profile in preclinical studies and early-phase clinical trials, with no evidence of significant toxicity or dose-limiting adverse events reported across various administration routes, including topical ophthalmic and systemic intravenous dosing. In a randomized, placebo-controlled phase I study involving single and multiple doses of synthetic TB4 in healthy volunteers, no grade 3 or higher adverse events occurred, and no serious adverse events were observed, supporting tolerability at doses up to 1,260 μg/kg. Preclinical toxicology evaluations have similarly found no organ-specific toxicities or genotoxic effects. In ophthalmic applications for , phase II trials of TB4 eye drops (RGN-259) demonstrated safety and tolerability, with no significant adverse events leading to subject withdrawal and only mild, transient ocular irritation reported in a minority of participants. Systemic studies, including a phase Ib trial in healthy volunteers assessing and immune responses, reported no serious adverse events, though full results emphasized monitoring for potential without confirmed issues. Across these trials, common mild effects, when noted, included injection-site reactions or transient , but incidence rates were comparable to groups. Long-term safety data remain limited due to TB4's investigational status, with most trials spanning weeks to months rather than years. Theoretical concerns include its pro-angiogenic properties potentially exacerbating proliferative conditions like cancer, though no causal links have been established in trials. Regarding potential interactions with medical devices, no evidence of adverse effects between thymosin beta-4 or its analog TB-500 and metal implants (e.g., titanium hardware) has been reported in the literature; in fact, studies suggest that thymosin beta-4 may enhance osteoblast adhesion to titanium surfaces, potentially aiding in implant integration. As peptides primarily target cellular processes rather than inert materials like metals, direct adverse interactions are unlikely. Off-label or unregulated use, often via synthetic analogs like TB-500, lacks rigorous oversight, and pediatric safety has not been established. Ongoing phase II/III trials continue to prioritize adverse event monitoring to refine the profile.

Controversies and Regulatory Issues

Doping in Sports and Bans

Thymosin beta-4 (TB4) and its synthetic derivatives, such as TB-500, have been implicated in sports doping due to their roles in accelerating tissue repair, reducing , and enhancing recovery from injuries, which can provide athletes with an unfair competitive edge by enabling faster return to training and competition. TB-500, a synthetic fragment derived from the active region of TB4, mimics its actin-sequestering properties to regulate actin dynamics, promoting cell migration and tissue repair in preclinical models; this contributes to potential improvements in flexibility, endurance recovery, and sustained tissue resilience, though human evidence remains limited. These properties stem from TB4's ability to promote , , and , allowing for potentially shortened downtime from musculoskeletal injuries common in high-intensity sports. The (WADA) classifies TB4 under S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics, prohibiting it at all times, both in and out of competition, as it falls into the category of substances with similar chemical structure or biological effect to endogenous growth factors. This ban includes any form of administration, whether via injection, oral, or other routes, targeting exogenous use that exceeds physiological levels. TB-500, a fragment of TB4 (Ac-LKKTETQ), is explicitly named as a and shares the same prohibition status under S2.3 as a growth factor modulator affecting regenerative capacity. Prior to January 1, , TB4 was prohibited under broader S2 categories for growth factors, but it was specifically enumerated in the 2018 list alongside TB-500 to clarify its status and deter evasion. Notable enforcement cases include the 2012-2013 (AFL) Essendon Football Club supplements saga, where 34 players were administered TB4 as part of an experimental program overseen by sports scientist ; the (CAS) ruled in January 2016 that this constituted a doping violation, imposing two-year suspensions backdated to March 2015, allowing the players to return by early 2017. Similar allegations arose in the National Rugby League's Cronulla Sharks case around the same period, where TB4 use was investigated amid broader supplementation concerns, though not all led to individual player bans due to evidentiary challenges. These incidents highlighted detection difficulties, as TB4's endogenous presence requires advanced testing for elevated levels or metabolites, prompting WADA to refine analytical methods. Penalties for TB4 violations remain severe, with WADA stipulating ineligibility periods of up to four years for first offenses involving non-specified substances like TB4, depending on intent and circumstances, as enforced by national anti-doping agencies. Despite claims from figures like Dank that TB4 was not explicitly listed pre-2018, WADA's classifications encompassed it under analogous prohibitions, underscoring the agency's intent to regulate recovery-enhancing peptides regardless of precise . The , beginning in 2012, represents one of the most prominent scandals involving thymosin beta-4 (TB4) in . Under a controversial supplements program overseen by sports scientist , 34 Essendon players in the Australian Football League (AFL) were administered TB4 injections, a substance prohibited by the code as a with potential performance-enhancing effects on tissue repair and recovery. The Australian Sports Anti-Doping Authority (ASADA) issued show-cause notices in 2014 based on , including import records and witness statements, despite no players testing positive for TB4. In January 2016, the (CAS) upheld anti-doping violations, imposing two-year bans on the players, backdated to March 2015, allowing their return by November 2016; the tribunal cited the players' failure to rebut evidence of TB4 use as sufficient for guilt under the WADA code's standard. Former coach contested the ruling, asserting the players' innocence and criticizing the reliance on non-analytical evidence, while Essendon faced fines and draft penalties totaling over AUD 2 million. A 2019 AFL Anti-Doping Tribunal decision later cleared the players of intentional doping but did not overturn the CAS bans, highlighting inconsistencies in evidentiary thresholds across jurisdictions. Legal debates surrounding TB4 in the Essendon case centered on its status under the WADA prohibited list, with ASADA maintaining it was explicitly banned as a thymosin-related , while defense arguments questioned whether the substance imported matched the banned form and emphasized TB4's endogenous nature in the body, potentially blurring lines between therapeutic and illicit use. Critics, including legal analysts, argued the case exemplified overreach in doping enforcement, as performance benefits from TB4—primarily actin sequestration for —remain empirically modest compared to traditional anabolic agents, yet triggered sanctions under precautionary WADA principles rather than proven harm or advantage. A parallel investigation into the Cronulla NRL club in implicated 14 players in TB4 supplementation via Dank's program, prompting ASADA probes into potential breaches; however, no suspensions resulted, as evidence was deemed insufficient for violations, fueling debates on and the challenges of proving misuse without direct detection methods. These cases underscore broader tensions in sports law over TB4's regulatory classification, with WADA's zero-tolerance stance prioritizing abuse prevention amid limited pharmacokinetic data on exogenous dosing, despite calls for nuanced thresholds distinguishing physiological restoration from enhancement.

Concerns Over Unregulated Use and Purity

Thymosin beta-4 (TB4) is not approved by the U.S. (FDA) for human therapeutic use, limiting its availability to research-grade products or pharmacies, which often operate under less stringent oversight. This regulatory gap has led to widespread unregulated distribution through online vendors and black-market channels, where TB4 and derivatives like TB-500 are marketed as performance enhancers or healing agents despite explicit warnings against human consumption. Purity concerns arise primarily from non-pharmaceutical synthesis methods used by many suppliers, resulting in products contaminated with impurities, degradation products, or incorrect sequences that can trigger immune responses or reduce efficacy. The FDA has categorized TB4 as a bulk substance posing significant safety risks for compounding due to potential from impurities and a lack of adequate human exposure data to assess long-term effects. Independent analyses of falsified or unregulated peptides, including those similar to TB4, have detected impurities such as , residual solvents, and microbial contaminants, exacerbating risks of adverse reactions like allergic responses or infections upon injection. Unregulated dosing protocols, often derived from anecdotal reports rather than clinical evidence, compound these issues, with users self-administering doses ranging from 2 to 10 mg weekly without , potentially leading to overdosing or underdosing that heightens risks from impure formulations. Reports from regulatory bodies highlight that black-market sourcing increases exposure to products, where TB4 may be diluted or substituted, undermining any purported benefits while elevating chances of unforeseen health complications such as or organ stress. Compounding pharmacies, while intended for , face scrutiny for inconsistent quality control, as evidenced by FDA warnings against using TB4 in such preparations absent robust safety data.

Recent Developments and Future Directions

Emerging Research (2023–2025)

Research published in early 2023 highlighted thymosin beta-4's (TB4) potential in anti-aging regenerative therapies, demonstrating its expression in the developing mammalian heart where it promotes cardiac and , while in adult models it enhances myocyte , increases coronary vessel numbers, and alters patterns conducive to regeneration, independent of induction. These findings, derived from animal models, suggest TB4 reactivates embryonic-like regenerative programs in mature cardiac tissue, though human translation remains preclinical. A 2025 study on cardiac remodeling showed TB4 modulates post-injury processes by supporting myocardial cell survival, promoting coronary regrowth, and influencing differentiation, with effects observed in rodent models of . Similarly, investigations into neurodegenerative applications reported in 2025 indicated TB4 rescues defects and reduces amyloid-beta accumulation in familial cerebral organoids, pointing to cytoskeletal stabilization as a mechanism for . Preclinical studies have further demonstrated that TB4 reduces microglial activation, mitigates amyloid toxicity, and alleviates oxidative stress in Alzheimer's disease models, leading to improved outcomes in organoids and animal models of neurodegeneration. In contexts, a 2025 analysis emphasized TB4's investigational role in tissue repair but noted insufficient clinical evidence for routine recommendation, with preclinical data supporting actin dynamics modulation for accelerated epithelial regeneration. Combined with selenium, TB4 showed synergistic effects in 2025 diabetic wound models, enhancing healing via reduced and improved insulin signaling, though limited to and animal validations. A 2024 review mapped TB4 expression patterns across organs during fetal development, correlating higher levels with proliferative tissues and suggesting developmental insights for therapeutic targeting. No new phase III clinical trials specific to TB4 emerged in this period beyond ongoing ophthalmic applications, with research prioritizing mechanistic preclinical advancements over large-scale . These studies underscore TB4's multi-faceted actin-binding properties but highlight the need for rigorous causal validation in systems to distinguish correlative from interventionally effective outcomes.

Market and Therapeutic Potential

Thymosin beta-4 (TB4) lacks regulatory approval for human therapeutic use from agencies such as the FDA as of October 2025, confining its commercial availability to research-grade peptides supplied by biochemical vendors for laboratory and preclinical applications. Synthetic variants like TB-500, a TB4 fragment, circulate in unregulated online markets purportedly for performance enhancement or injury recovery, though manufacturers disclaim human consumption and quality control remains inconsistent. Veterinary applications are similarly off-label and undocumented in approved formulations, with no dedicated commercial products identified. Biopharmaceutical efforts center on RegeneRx Biopharmaceuticals, which develops TB4-derived formulations including RGN-259, an ophthalmic solution targeting neurotrophic (NK) and dry eye disease. Prior Phase 2/3 trials indicated improvements in corneal and symptoms, with effects observable within days, positioning it for potential entry into the NK market valued at $324 million by 2027. However, the July 2025 SEER-3 Phase 3 trial in missed its primary endpoint for complete corneal , though secondary outcomes suggested tolerability and partial efficacy, prompting reevaluation of trial design rather than abandonment. RegeneRx's broader pipeline explores TB4 for cardiac repair (RGN-352) and dermal wounds (RGN-137), supported by preclinical data on and anti-inflammation, but human evidence remains Phase 2-limited. Therapeutic potential spans , with TB4's actin-sequestering and migration-promoting mechanisms offering promise for chronic wounds, , and neurodegeneration, as evidenced by animal models and small human studies. Market forecasts project global TB4 sales growth from approximately $450 million in 2023 to $980 million by 2032, driven by demand in tissue repair and anti-aging , though these estimates from industry analysts may incorporate speculative unregulated segments and overlook approval barriers. Success hinges on overcoming regulatory scrutiny, including FDA reclassification of TB4 as a biologic in 2020, which extended timelines, and associations with sports doping that complicate clinical advancement. Without successes, therapeutic commercialization remains prospective, potentially yielding high-value status in underserved indications like NK if efficacy is substantiated.

References

  1. https://www.uniprot.org/uniprotkb/P62328/entry
  2. https://www.ncbi.nlm.nih.gov/gene/7114
  3. https://omim.org/entry/300159
  4. https://pubmed.ncbi.nlm.nih.gov/20179146/
  5. https://www.genecards.org/cgi-bin/carddisp.pl?gene=TMSB4X
  6. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/thymosin-beta-4
  7. https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.09-142307
  8. https://www.sciencedirect.com/science/article/pii/S1567576923000644
  9. https://www.mdpi.com/2073-4409/7/10/145
  10. https://academic.oup.com/jnci/article/95/22/1674/2606660
  11. https://www.ahajournals.org/doi/10.1161/circresaha.111.258616
  12. https://pubmed.ncbi.nlm.nih.gov/17600284/
  13. https://nyaspubs.onlinelibrary.wiley.com/doi/abs/10.1196/annals.1415.045
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC319967/
  15. https://www.pnas.org/doi/10.1073/pnas.78.2.1162
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC517612/
  17. https://pubmed.ncbi.nlm.nih.gov/12581423/
  18. https://pubmed.ncbi.nlm.nih.gov/7945275/
  19. https://pubmed.ncbi.nlm.nih.gov/8416954/
  20. https://www.sciencedirect.com/science/article/pii/S0021925820667400
  21. https://pubmed.ncbi.nlm.nih.gov/36464872/
  22. https://www.molbiolcell.org/doi/10.1091/mbc.3.9.1015
  23. https://www.rcsb.org/structure/1t44
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC4217450/
  25. https://www.sciencedirect.com/science/article/pii/009286749390544Z
  26. https://pubmed.ncbi.nlm.nih.gov/30876947/
  27. https://pubmed.ncbi.nlm.nih.gov/29508629/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC3101037/
  29. https://www.nature.com/articles/ncomms3081
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC3273210/
  31. https://onlinelibrary.wiley.com/doi/10.1155/2018/9630175
  32. https://www.mdpi.com/1422-0067/24/4/3439
  33. https://www.spandidos-publications.com/10.3892/br.2017.952
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC4187393/
  35. https://www.ahajournals.org/doi/10.1161/hypertensionaha.118.10952
  36. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026912
  37. https://pubmed.ncbi.nlm.nih.gov/10469335/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/
  39. https://pubmed.ncbi.nlm.nih.gov/22074294/
  40. https://pubmed.ncbi.nlm.nih.gov/23084823/
  41. https://pubmed.ncbi.nlm.nih.gov/22962027/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC8228050/
  43. https://www.sciencedirect.com/science/article/abs/pii/S008367291630005X
  44. https://pubmed.ncbi.nlm.nih.gov/27450738/
  45. https://pubmed.ncbi.nlm.nih.gov/15037013/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/
  47. https://www.ahajournals.org/doi/10.1161/circresaha.111.259846
  48. https://pubmed.ncbi.nlm.nih.gov/9194528/
  49. https://pubmed.ncbi.nlm.nih.gov/22652458/
  50. https://stemcellres.biomedcentral.com/articles/10.1186/s13287-021-02687-x
  51. https://www.spandidos-publications.com/10.3892/ijmm.2020.4701
  52. https://www.researchgate.net/publication/354883470_Recombinant_TAT-Thymosin_b-4_Promotes_Angiogenesis_by_Activating_VEGFR2_Signaling_Pathway
  53. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0130040
  54. https://pubmed.ncbi.nlm.nih.gov/14657002/
  55. https://pubmed.ncbi.nlm.nih.gov/17254567/
  56. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1458684/full
  57. https://www.dovepress.com/thymosin-4-regulates-tissue-inflammatory-response-in-mouse-nonalcoholi-peer-reviewed-fulltext-article-JIR
  58. https://pubmed.ncbi.nlm.nih.gov/10581087/
  59. https://pubmed.ncbi.nlm.nih.gov/17600280/
  60. https://transmedcomms.biomedcentral.com/articles/10.1186/s41231-016-0008-y
  61. https://pubmed.ncbi.nlm.nih.gov/20536453/
  62. https://pubmed.ncbi.nlm.nih.gov/35712678/
  63. https://www.sciencedirect.com/science/article/abs/pii/S0083672916300048
  64. https://pubmed.ncbi.nlm.nih.gov/29550018/
  65. https://pubmed.ncbi.nlm.nih.gov/27450736/
  66. https://www.ahajournals.org/doi/10.1161/JAHA.124.038177
  67. https://www.droracle.ai/articles/234798/tb-500-peptide
  68. https://www.orthoandwellness.com/blog/tb-500-exposed-the-risks-outweigh-the-benefits
  69. https://www.tga.gov.au/sites/default/files/foi-1132-1819-01.pdf
  70. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=416613
  71. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  72. https://drdanwool.com/blog/thymosin-beta-4
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC10403815/
  74. https://clinicaltrials.gov/study/NCT01387347
  75. https://clinicaltrials.gov/study/NCT00311766
  76. https://clinicaltrials.gov/study/NCT00832091
  77. https://livvnatural.com/peptides-for-hair-growth-the-science-behind-fuller-thicker-hair/
  78. https://www.centerwatch.com/clinical-trials/listings/NCT05984134/efficacy-and-safety-study-of-thymosin-beta-4-in-patients-with-acute-myocardial-infarction
  79. https://clinicaltrials.gov/study/NCT04555850
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC6556887/
  81. https://globalrph.com/2025/11/bpc-157-and-tb-500-background-indications-efficacy-and-safety/
  82. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.767785/full
  83. https://www.nature.com/articles/s41598-018-28861-5
  84. https://pmc.ncbi.nlm.nih.gov/articles/PMC4445951/
  85. https://www.mdpi.com/1422-0067/24/1/554
  86. https://clinicaltrials.gov/study/NCT02597803
  87. https://www.tandfonline.com/doi/abs/10.1080/14712598.2018.1486818
  88. https://www.sciencedirect.com/science/article/abs/pii/S0083672916300255
  89. https://www.sciencedirect.com/science/article/abs/pii/S1567576923002096
  90. https://clinicaltrials.gov/study/NCT01311518
  91. https://nyaspubs.onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2010.05474.x
  92. https://www.innerbody.com/thymosin-beta-4-and-tb-500
  93. https://pubmed.ncbi.nlm.nih.gov/25826322/
  94. https://a4m.com/assets/pdf/covid-19-resources/Thymosin%2520beta%25204%2520prof%2520monograph.pdf
  95. https://pubmed.ncbi.nlm.nih.gov/26369135/
  96. https://www.wada-ama.org/en/prohibited-list
  97. https://journals.sagepub.com/doi/10.1177/03635465251357593
  98. https://www.sportintegrity.gov.au/substances/thymosin-beta-4
  99. https://www.wada-ama.org/sites/default/files/2024-09/2025list_en_final_clean_12_september_2024.pdf
  100. https://www.usada.org/athlete-advisory/2018-prohibited-list-summary-of-major-changes/
  101. https://www.sportresolutions.com/news/asada-responds-to-essendon-doping-scandal-which-saw-34-players-banned
  102. https://theconversation.com/cronulla-sharks-and-thymosin-beta-4-is-it-doping-12694
  103. https://www.sciencedirect.com/science/article/pii/S1570023224000412
  104. https://www.theage.com.au/sport/afl/thymosin-beta-4-not-on-wada-banned-list-stephen-dank-20150329-1ma7do.html
  105. https://www.theage.com.au/sport/afl/essendon-supplements-scandal-tb4-was-always-banned-says-asada-20191016-p53167.html
  106. https://www.theguardian.com/sport/2016/jan/18/james-hird-defends-34-banned-players-and-says-they-are-innocent-of-doping
  107. https://www.theguardian.com/sport/2019/oct/16/a-stitch-up-new-twist-in-essendon-supplements-saga-reported
  108. https://www.monash.edu/news/opinions/doping-and-bad-arguments
  109. https://pubmed.ncbi.nlm.nih.gov/23421910/
  110. https://honehealth.com/edge/fda-peptide-ban/
  111. https://www.mcgill.ca/oss/article/critical-thinking-health-and-nutrition/human-lab-rats-injecting-themselves-peptides
  112. https://www.sciencedirect.com/science/article/abs/pii/S0039914018306283
  113. https://barpathfitness.com/blog/peptide-therapy-for-injuries-performance-health-and-more/
  114. https://www.getrecall.ai/summary/peptides/benefits-and-risks-of-peptide-therapeutics-for-physical-and-mental-health
  115. https://www.fda.gov/media/94155/download
  116. https://pubmed.ncbi.nlm.nih.gov/36709593/
  117. https://www.regenerx.com/2023-01-31-Thymosin-Beta-4-Research-Leads-Toward-Potential-Future-Anti-aging-Therapy
  118. https://pubmed.ncbi.nlm.nih.gov/40362372/
  119. https://www.mdpi.com/1422-0067/26/9/4131
  120. https://www.sciencedirect.com/science/article/pii/S221367112500205X
  121. https://pubmed.ncbi.nlm.nih.gov/40816274/
  122. https://link.springer.com/article/10.1186/s12974-021-02166-3
  123. https://pubmed.ncbi.nlm.nih.gov/36878045/
  124. https://www.droracle.ai/articles/268380/peptide-thymosin-4
  125. https://link.springer.com/article/10.1007/s44340-025-00015-0
  126. https://pmc.ncbi.nlm.nih.gov/articles/PMC11240739/
  127. https://www.sciencedirect.com/science/article/abs/pii/S1567576923002734
  128. https://www.droracle.ai/articles/269789/which-of-the-non-fda-approved-peptides-are-likely-legi
  129. https://www.paragonsportsmedicine.com/peptides/tb-500
  130. https://www.regenerx.com/RGN-259
  131. https://www.ainvest.com/news/regenerx-biopharmaceuticals-unlocking-growth-4-innovation-strategic-capital-allocation-2507/
  132. https://www.ophthalmologytimes.com/view/hlb-therapeutics-misses-primary-endpoint-in-phase-3-seer-3-trial-of-rgn-259
  133. https://www.regenerx.com/clinical-trials
  134. https://pubmed.ncbi.nlm.nih.gov/17947592/
  135. https://dataintelo.com/report/global-thymosin-beta-4-sales-market
  136. https://www.prnewswire.com/news-releases/regenerx-advisory-on-reclassification-of-thymosin-beta-4-from-drug-to-biologic-301066219.html
  137. https://www.regenerx.com/news-releases?l=100
Add your contribution
Related Hubs
User Avatar
No comments yet.